Exhibit 13.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), Feng Tian, Ph.D., President, Chief Executive Officer and Chairman of the Board of Directors of Ambrx Biopharma Inc. (the “Company”), hereby certifies that, to the best of his knowledge:
| 1. | The Company’s Annual Report on Form 20-F for the year ended December 31, 2021, to which this Certification is attached as Exhibit 13.1 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and |
| 2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
| Date: April 26, 2022 | By: | /s/ Feng Tian, Ph.D. | ||||
| Feng Tian, Ph.D. | ||||||
| President, Chief Executive Officer and Chairman of the Board of Directors (Principal Executive Officer) | ||||||